NO975140L - Transdermal therapeutic system (TTS) for the administration of testosterone - Google Patents

Transdermal therapeutic system (TTS) for the administration of testosterone

Info

Publication number
NO975140L
NO975140L NO975140A NO975140A NO975140L NO 975140 L NO975140 L NO 975140L NO 975140 A NO975140 A NO 975140A NO 975140 A NO975140 A NO 975140A NO 975140 L NO975140 L NO 975140L
Authority
NO
Norway
Prior art keywords
testosterone
tts
therapeutic system
administration
transdermal therapeutic
Prior art date
Application number
NO975140A
Other languages
Norwegian (no)
Other versions
NO975140D0 (en
Inventor
Wilfried Fischer
Daniel Bracher
Original Assignee
Hexal Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hexal Ag filed Critical Hexal Ag
Publication of NO975140D0 publication Critical patent/NO975140D0/en
Publication of NO975140L publication Critical patent/NO975140L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Det beskrives et transdermalt terapeutisk system for administrasjon av testosteron eller et testosleronderivat som aktiv ingrediens.A transdermal therapeutic system for administering testosterone or a testoslerone derivative is described as an active ingredient.

NO975140A 1995-05-10 1997-11-07 Transdermal therapeutic system (TTS) for the administration of testosterone NO975140L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19517145A DE19517145C2 (en) 1995-05-10 1995-05-10 Transdermal therapeutic system (TTS) for administration of testosterone
PCT/EP1996/002013 WO1996035427A1 (en) 1995-05-10 1996-05-10 Transdermal therapeutic system for administering testosterone

Publications (2)

Publication Number Publication Date
NO975140D0 NO975140D0 (en) 1997-11-07
NO975140L true NO975140L (en) 1997-11-10

Family

ID=7761562

Family Applications (1)

Application Number Title Priority Date Filing Date
NO975140A NO975140L (en) 1995-05-10 1997-11-07 Transdermal therapeutic system (TTS) for the administration of testosterone

Country Status (17)

Country Link
EP (1) EP0825865B1 (en)
JP (1) JPH11504643A (en)
CN (1) CN1183723A (en)
AT (1) ATE208200T1 (en)
AU (1) AU702710B2 (en)
BR (1) BR9608255A (en)
CA (1) CA2220358A1 (en)
CZ (1) CZ287678B6 (en)
DE (2) DE19517145C2 (en)
DK (1) DK0825865T3 (en)
HU (1) HUP9801130A3 (en)
NO (1) NO975140L (en)
NZ (1) NZ308516A (en)
PL (1) PL323145A1 (en)
SK (1) SK149797A3 (en)
WO (1) WO1996035427A1 (en)
ZA (1) ZA963743B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1429697A (en) * 1995-12-29 1997-07-28 Cygnus, Inc. Systems and methods for the transdermal administration of androgenic agents
DE69716737T2 (en) * 1996-07-03 2003-03-20 Alza Corp., Palo Alto DEVICES FOR DRUG DELIVERY AND MANUFACTURING METHOD
US6007837A (en) * 1996-07-03 1999-12-28 Alza Corporation Drug delivery devices and process of manufacture
DE19646050A1 (en) * 1996-11-08 1998-05-14 Labtec Gmbh Transdermal therapeutic system e.g. containing testosterone, melatonin
US6174545B1 (en) 1997-07-01 2001-01-16 Alza Corporation Drug delivery devices and process of manufacture
ES2226394T3 (en) * 1998-05-22 2005-03-16 Novosis Ag TRANSDERMAL SYSTEMS CONTAINING ACTIVE SUBSTANCE THAT IS RELEASED CONTROLLED IN TIME.
FR2793689B1 (en) * 1999-05-19 2001-08-24 Pf Medicament TRANSDERMAL DEVICE FOR THE ADMINISTRATION OF TESTOSTERONE OR A DERIVATIVE THEREOF
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US8173155B2 (en) 2004-06-01 2012-05-08 Hisamitsu Pharmaceutical Co., Inc. Adhesive patch
PT1937276E (en) 2005-10-12 2013-02-21 Besins Healthcare Luxembourg Improved testosterone gel and method of use
FR2895679B1 (en) * 2005-12-29 2012-06-08 Pf Medicament STABILIZATION OF TESTOSTERONE IN TRANSDERMAL DEVICES
CN101480399B (en) * 2008-09-25 2011-10-05 宋博 Application of andrusol in preparing medicament for treating asthenospermia
DE102011012712A1 (en) 2011-03-01 2012-09-06 Frank Lehmann-Horn Use of aldosterone receptor antagonists for the treatment of female sexual dysfunction

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4286592A (en) * 1980-02-04 1981-09-01 Alza Corporation Therapeutic system for administering drugs to the skin
US4725439A (en) * 1984-06-29 1988-02-16 Alza Corporation Transdermal drug delivery device
US4704282A (en) * 1984-06-29 1987-11-03 Alza Corporation Transdermal therapeutic system having improved delivery characteristics
US4849224A (en) * 1987-11-12 1989-07-18 Theratech Inc. Device for administering an active agent to the skin or mucosa
GB8804164D0 (en) * 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5152997A (en) * 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
MX9202350A (en) * 1991-05-20 1992-11-01 Alza Corp SKIN PENETRATION INCREMENTING COMPOSITIONS USING GLYCEROL MONOLINOLEATE.
CA2075517C (en) * 1992-04-01 1997-03-11 John Wick Transdermal patch incorporating a polymer film incorporated with an active agent
ATE184473T1 (en) * 1992-06-11 1999-10-15 Theratech Inc USE OF GLYCERINE TO ATTENUATE TRANSDERMAL DRUG ADMINISTRATION
EP0695177B1 (en) * 1993-04-20 1998-02-18 Hexal Ag Active substance-containing plaster
DE4313402A1 (en) * 1993-04-23 1994-10-27 Hexal Pharma Gmbh Transdermal preparation of active compound
US5460820B1 (en) * 1993-08-03 1999-08-03 Theratech Inc Method for providing testosterone and optionally estrogen replacement therapy to women

Also Published As

Publication number Publication date
EP0825865B1 (en) 2001-11-07
HUP9801130A2 (en) 1998-08-28
CZ287678B6 (en) 2001-01-17
BR9608255A (en) 1999-02-02
ATE208200T1 (en) 2001-11-15
CA2220358A1 (en) 1996-11-14
NO975140D0 (en) 1997-11-07
HUP9801130A3 (en) 2001-03-28
DE19517145C2 (en) 2000-02-24
EP0825865A1 (en) 1998-03-04
ZA963743B (en) 1996-11-18
NZ308516A (en) 1999-05-28
AU5805096A (en) 1996-11-29
SK149797A3 (en) 1998-05-06
DE19517145C1 (en) 1996-11-28
DK0825865T3 (en) 2002-02-18
CZ351297A3 (en) 1998-03-18
WO1996035427A1 (en) 1996-11-14
AU702710B2 (en) 1999-03-04
JPH11504643A (en) 1999-04-27
CN1183723A (en) 1998-06-03
PL323145A1 (en) 1998-03-16
DE59608150D1 (en) 2001-12-13

Similar Documents

Publication Publication Date Title
NO953874L (en) Pharmaceutical preparation containing lipophilic drugs
PL324552A1 (en) Plaster for pecutaneous administration of hormones
NO975140L (en) Transdermal therapeutic system (TTS) for the administration of testosterone
GB2305122B (en) Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
YU49026B (en) THE USE OF 17 ß -(N-TERT-BUTYLCARBAMOYIL)-4-AZA-5-ALPHA-ANDROST-1-ENE-3-ONE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ANDROGENIC ALOPECIA
PT1003490E (en) TRANSDERMIC THERAPEUTIC SYSTEM (TTS) FOR ADMINISTRATION OF SEXUAL HORMONES STEROIDES
DE69327432D1 (en) MEDICINE FOR Wounds and Hemorrhoid
NO942325D0 (en) Transdermally administered system containing acetylsalicylic acid for thrombosis therapy and cancer prophylaxis
PT1003477E (en) TRANSDERMIC THERAPEUTIC SYSTEM (TTS), CONTAINING (MET) ACRYLATE POLYMERS WITH AMONIO GROUPS FOR ADMINISTRATION OF LEVONORGESTREL
NO924723L (en) PHARMACOLOGICAL USE OF CERTAIN CYSTIN DERIVATIVES
RU95105973A (en) Method of toxoplasmosis severity decrease, pharmaceutical composition, use of rifamycin derivatives for preparing the medicinal preparations for toxoplasmosis treatment
KR950028767A (en) New Pharmaceutical Dosage Forms for Skin Pain Dosing
AU1277792A (en) Compositions for topical administration containing fluticasone propionate and oxiconazole or its salts
AU7291996A (en) Transdermal therapeutic system (tts) for the administration of drugs for treatment of drug dependency or drug addiction
NO167861C (en) ANALOGUE PROCEDURE FOR THE PREPARATION OF A NEW THERAPEUTIC ACTIVE INDOLOKINOL COMPOUND.
CA2331414A1 (en) Transdermal therapeutic system for the administration of candesartan
DK681887D0 (en) AZOLD DERIVATIVES, PROCEDURES FOR PROMOTION OF THEM, AND AGRICULTURAL / MARINE FUNGICID CONTAINING THE DERIVATIVE AS ACTIVE INGREDIENT
ATE296115T1 (en) SITE-SPECIFIC DRUG ADMINISTRATION
NO952234L (en) Transdermal administration system containing acetylsalicylic acid for antithrombosis therapy and cancer prevention
NO953003L (en) Use of ifenprodil and its diastereoisomers for the preparation of medical preparations
MX9302986A (en) MEDICINES CONTAINING METRIFONATE AND PROCEDURE FOR ITS PREPARATION
HUP0104941A2 (en) Blister containing more dose form of medicament
ECSP972295A (en) METHODS AND COMPOSITIONS TO MODULATE THE HUMAN SEXUAL RESPONSE
MX9705324A (en) Transdermal therapeutic system for dispensing (s)-3-methyl-5-(1-methyl-2-pyrrolidenyl)-isoxazole or one of its pharmaceutically acceptable salts.
AU4391196A (en) A transdermal therapeutic system for the administration of (s)-3-methyl-5-(1-methyl-2-pyrrolidinyl)-isoxazole or one of its pharmaceutically acceptable salts

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application